Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Total Liabilities (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Total Liabilities for 6 consecutive years, with $6.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 36.45% to $6.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.7 million, a 36.45% increase, with the full-year FY2024 number at $3.7 million, up 5.8% from a year prior.
  • Total Liabilities was $6.7 million for Q3 2025 at Inhibikase Therapeutics, down from $8.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $8.8 million in Q2 2025 to a low of $2.2 million in Q2 2021.
  • A 5-year average of $4.3 million and a median of $3.8 million in 2021 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: tumbled 55.25% in 2021, then skyrocketed 135.9% in 2025.
  • Inhibikase Therapeutics' Total Liabilities stood at $4.1 million in 2021, then decreased by 3.79% to $3.9 million in 2022, then dropped by 9.54% to $3.5 million in 2023, then rose by 5.8% to $3.7 million in 2024, then skyrocketed by 79.35% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Total Liabilities are $6.7 million (Q3 2025), $8.8 million (Q2 2025), and $8.6 million (Q1 2025).